# Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke

> **NCT00240643** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 640 (actual)

## Conditions studied

- Fibrillation, Atrial
- Atrial Fibrillation

## Interventions

- **DRUG:** SB424323

## Key facts

- **NCT ID:** NCT00240643
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2006-12
- **Final completion:** 2006-12
- **Target enrollment:** 640 (ACTUAL)
- **Last updated:** 2017-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00240643

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00240643, "Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00240643. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*